New Study in JNCCN Suggests Way to Predict Outcomes with High Accuracy Prior to Surgery for Pancreatic Cancer Patients
According to Mayo Clinic Comprehensive Cancer Center researchers, metabolic imaging (FDG-PET) in combination with traditional treatment response assessment methods can provide clinicians with critical information they need to guide therapy for pancreatic cancer patients. Increasingly impactful nature of research in JNCCN reflected in new high for the journal's Impact Factor, now 12.693....
YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine
BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics, announced that the Company received the approvals from the regulatory authorities of United Arab Emirates (UAE) and the Philippines to conduct Phase 2/3 clinical trials for its PIKA recombinant COVID-19 vaccine....
Nutromics raises US$14 million for its ground-breaking wearable diagnostic platform
MELBOURNE, Australia and SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Global MedTech start-up Nutromics has raised an additional US $14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion across Australia and the United States. Strategic investors included Dexcom Ventures, VU Venture Partners, and Artesian Investments. Nutromics patch (for illustrative purposes only)...
Pulnovo Medical Concludes Successfully the First Steering Committee Meeting
SHANGHAI, Sept. 8, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, today announced that it has successfully concluded the first Steering Committee meeting for PADN Global Clinical Trial. Photo of the scene As members of the Steering Committee, the world's leading cardiopulmonary experts presented and discussed about the future clinical workflow...
Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022
HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors HMBD-001 has the potential to fully block both ligand-dependent and -independent HER3 signaling SINGAPORE, Sept. 8, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Johann de...
FII Institute Looks to Identify the highest priority for each segment of society at New York Summit
RIYADH, Saudi Arabia, Sept. 8, 2022 /PRNewswire/ -- In one month's time, the Future Investment Initiative (FII) Institute will host PRIORITY, a summit in New York City that will bring together people from all walks of life – leaders, policymakers, CEOs, students, volunteers, academics, athletes, investors, and more – to discuss the...
The first AXA Medical Centre officially unveils
Partnering with EC Healthcare to offer one-stop health management services AXA fulfills its Payer-to Partner strategy to become customers' lifelong partner HONG KONG, Sept. 8, 2022 /PRNewswire/ -- AXA and EC Healthcare today (8 September) held the "AXA Medical Centre Unveiling and AXA Hong Kong and EC Healthcare MOU Signing Ceremony", pledging to work together to provide professional, quality,...
ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS
International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the threat of AMR Debiopharm will join the action-focused discussions around this silent...
Cytiva launches BioChallenge in Southeast Asia to support biotech startup development
Cytiva's BioChallenge launches in Singapore, Indonesia, Thailand and Vietnam to accelerate the growth of promising emerging biotechs BioChallenge facilitates access to Cytiva's services and expertise to scale up efficiently, mitigate risks and reduce time to go to market Application period is open between 1 September and 31 December 2022 SINGAPORE, Sept. 8, 2022 /PRNewswire/ -- Cytiva, a...
The Outbreak of COVID-19 Unlocked the Demand for Antimicrobial Technologies
Innovations triggered by the pandemic are pushing industries to adopt long-lasting antimicrobial technology, says Frost & Sullivan SAN ANTONIO, Sept. 8, 2022 /PRNewswire/ -- The outbreak of COVID-19 unlocked the demand for antimicrobial technologies across sectors, finds Frost & Sullivan's recent analysis, Growth Opportunities for Global Antimicrobial Technologies Enabled by COVID-19. The pandemic triggered innovations in antimicrobial technologies and...
